Biogenvs.Gilead Sciences
BIIB vs GILD · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Gilead Sciences is about 5.5× larger than Biogen by market cap; Gilead Sciences trades at the lower P/E (17.5 vs 21.3); year to date, Biogen leads (+13.2% vs +5.8%).
Side by side
| BIIB | GILD | |
|---|---|---|
| Market cap | $29.3B | $162B |
| Price | $199.15 | $129.83 |
| Today | +0.1% | −3.7% |
| Return YTD | +13.2% | +5.8% |
| Return 1Y | +47.2% | +13.3% |
| P/E | 21.3 | 17.5 |
| P/S | 2.9 | 5.4 |
| P/B | 1.6 | 6.9 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
BiogenBIIB
American biotech company focused on neurological diseases — including Alzheimer's (Leqembi, with Eisai) and MS.
Full BIIB profile →Gilead SciencesGILD
American biotech company and global leader in HIV treatment, with a growing oncology portfolio.
Full GILD profile →More comparisons in Biotech & innovation
See where BIIB and GILD sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →